Anixa biosciences and moffitt cancer center complete dosing in third cohort in ovarian cancer car-t clinical trial

San jose, calif. , feb. 26, 2025 /prnewswire/ -- anixa biosciences, inc. ("anixa" or the "company") (nasdaq: anix), a biotechnology company focused on the treatment and prevention of cancer, today announced has it has dosed its final patient in the third cohort of its ongoing phase 1 clinical trial evaluating its novel chimeric antigen receptor-t cell (car-t) therapy for recurrent ovarian cancer.
CAR Ratings Summary
CAR Quant Ranking